A novel drug-delivery method that uses gemcitabine-laden poly(lactic-co-glycolic acid)-based microparticles (MPs) to treat pancreatic cancer is under investigation — and researchers running the experiment at Mount Sinai in New York, New York, were able to show that these encapsulations could promote cancer-cell-killing effects and modulate drug resistance in vitro and in vivo when compared with blank, unloaded MPs.
The investigators presented their results during the 2018 AACR Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston, Massachusetts. Read more . . .